[HTML][HTML] Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
Leukemia, 2014•nature.com
7 Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative
neoplasms. Hematology 2012; 17 (Suppl 1): S129–S132. 8 Quintás-Cardama A, Vaddi K,
Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective JAK1/2
inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative
neoplasms. Blood 2010; 115: 3109–3117.
neoplasms. Hematology 2012; 17 (Suppl 1): S129–S132. 8 Quintás-Cardama A, Vaddi K,
Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective JAK1/2
inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative
neoplasms. Blood 2010; 115: 3109–3117.
7 Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology 2012; 17 (Suppl 1): S129–S132. 8 Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109–3117.
nature.com